Evanta

Tavanta Therapeutics is a specialty pharmaceutical company focused on developing novel therapies for patients with significant unmet medical needs. The company utilizes a risk-balanced approach to drug development, leveraging its proprietary High Throughput (HT) Matrix Screening and Peptide Conjugate Development (PCD) platforms to enhance the performance of established molecules and discover new therapeutic candidates. Tavanta's clinical pipeline is led by programs in oncology, specifically targeting metastatic prostate cancer, alongside late-stage candidates for chronic anal fissures and tuberous sclerosis complex. The company was formed through a reorganization of Druggability Technologies and maintains a strategic focus on both internal R&D and external partnerships.